Xtx Topco LTD Akebia Therapeutics, Inc. Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 44,267 shares of AKBA stock, worth $81,451. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,267

Holding current value

$81,451

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $41,610 - $68,613	44,267 New	44,267 $58,000
Q4 2023 Feb 13, 2024	SELL	$0.8 - $1.28 $31,088 - $49,742	-38,861 Reduced 28.06%	99,645 $123,000
Q3 2023 Nov 13, 2023	SELL	$0.87 - $1.84 $174,749 - $369,584	-200,861 Reduced 59.19%	138,506 $157,000
Q2 2023 Aug 14, 2023	BUY	$0.51 - $1.43 $173,077 - $485,294	339,367 New	339,367 $312,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $32,765 - $68,602	-102,392 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.72 - $2.93 $54,457 - $221,610	75,635 Added 282.67%	102,392 $74,000
Q4 2021 Feb 11, 2022	BUY	$2.26 - $3.34 $60,470 - $89,368	26,757 New	26,757 $60,000
Q3 2021 Nov 12, 2021	SELL	$2.35 - $3.88 $48,384 - $79,885	-20,589 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$2.83 - $4.2 $58,266 - $86,473	20,589 New	20,589 $78,000

Others Institutions Holding AKBA

# of Institutions

121

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

Black Rock Inc. New York, NY

11.6M
Shares

$21.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$18.5 Million
0.0% of portfolio
Satter Management Co., L.P.

5.75M
Shares

$10.6 Million
13.23% of portfolio
Geode Capital Management, LLC Boston, MA

4.75M
Shares

$8.75 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

3.72M
Shares

$6.84 Million
0.01% of portfolio

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $338M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account